Contribute Try STAT+ Today

For more than a decade, psychiatry has been a graveyard for new medicines. While in the 1990s and 2000s the pharmaceutical industry became rich off of the profits from big-name drugs like Prozac and Abilify, in recent years many firms have exited the neuroscience business entirely. Recent attempts to re-enter it have been underwhelming.

On Thursday, ARCH Venture Partners, one of the biotechnology industry’s top venture capital firms, revealed new details about a company it has started to try to re-ignite the development of medicines for diseases such as depression, schizophrenia, and Alzheimer’s. Neumora, a roll-up of assets from several biotech firms and from the drug giant Amgen, is backed with $500 million in funding from ARCH and at least 12 other investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment